FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer

FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer

Source: 
BioSpace
snippet: 

The FDA has approved the combination regimen of Merck’s Keytruda (pembrolizumab) and Seagen and Astellas’ Padcev (enfortumab vedotin-ejfv) for the first-line treatment of locally advanced or metastatic urothelial carcinoma, the companies announced Monday.